Artgen reported for 6 months of 2026 under RAS

Net profit of Artgen Biotech under RAS for 6 months of 2026 amounted to ₽53.6 million, an increase of 19.9% compared to ₽44.7 million in the previous year. Revenue increased by 41.2% to ₽104.9 million, compared to ₽74.3 million a year earlier.